Economic Value of Next-Generation Vaccines in Türkiye: A Comparative Evaluation
Abstract
Background: Vaccination programs are among the most effective and sustainable public health interventions for preventing infectious diseases. This study aims to comparatively evaluate the cost-effectiveness of potential H pylori, Meningococcal, and Leishmaniasis vaccines currently being developed within the scope of the KORTUP (National Platform for Prevention and Treatment), TÜBİTAK 1004 Project in Türkiye.
Methods: This study compares findings from three separate economic evaluation models. A Markov modeling approach was employed in all analyses. The primary outcome measures included costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Results were interpreted using willingness-to-pay (WTP) thresholds based on Türkiye’s gross domestic product (GDP) per capita. The base-case threshold was set at USD 15,395, and an alternative scenario threshold of USD 30,790 (twice the base value) was also considered.
Results: The comparative analysis indicates that all three vaccine candidates may be cost-effective in Türkiye under specific model assumptions. In the base-case analysis, the ICER was estimated at USD 1,583 per QALY gained for the H pylori vaccine, USD 11,652/QALY for the Meningococcal vaccine, and USD 20,444/QALY for the Leishmaniasis vaccine. Accordingly, the H pylori and Meningococcal vaccines appear to be cost-effective under the GDP per capita threshold of USD 15,395, whereas the Leishmaniasis vaccine may be considered cost-effective only under the higher threshold of USD 30,790.
Conclusions: Comparative economic evaluation of vaccine candidates targeting different diseases can support more efficient allocation of limited healthcare resources by prioritizing interventions that generate the greatest societal benefit.
Key messages: • The Helicobacter pylori vaccine appears to be the most cost-effective option among the three candidates, followed by the meningococcal and leishmaniasis vaccines.
• Assessing the economic value of domestically developed vaccine candidates is strategic for informing national immunization policies and health technology assessment in Türkiye.
Related
- Global return-on-investment of COVID-19 vaccines in the first year of the vaccination programme: A model-based economic evaluation
- Comparative Phytochemical and Biological Evaluation of Four Thymus Species From Türkiye for Dermocosmetic Applications
- Graph-Enhanced Retrieval-Augmented Generation for Postoperative Patient Question Answering: A Comparative Evaluation of Knowledge Graph, Retrieval-Augmented Generation, and Hybrid GraphRAG Approaches
- Seroprevalence of Major Viral Pathogens Associated with Bovine Respiratory Disease in Cattle in Türkiye and Scenario-Based Estimates of Economic Loss
- Comparative evaluation of metagenomic and targeted next-generation sequencing for pathogen detection in bronchoalveolar lavage fluid from patients with lower respiratory tract infections: a retrospective cohort study.
BibTeX
@article{tosunoglu2026economic,
title = {{Economic Value of Next-Generation Vaccines in Türkiye: A Comparative Evaluation}},
author = {M Tosunoğlu and M Abay and MK Sözmen and B Kılıç},
journal = {The European Journal of Public Health},
year = {2026},
month = oct,
doi = {10.1093/eurpub/ckag169.1829},
url = {https://doi.org/10.1093/eurpub/ckag169.1829},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Economic Value of Next-Generation Vaccines in Türkiye: A Comparative Evaluation
AU - M Tosunoğlu
AU - M Abay
AU - MK Sözmen
AU - B Kılıç
PY - 2026
DA - 2026/10/01
JO - The European Journal of Public Health
DO - 10.1093/eurpub/ckag169.1829
UR - https://doi.org/10.1093/eurpub/ckag169.1829
AB - Background: Vaccination programs are among the most effective and sustainable public health interventions for preventing infectious diseases. This study aims to comparatively evaluate the cost-effectiveness of potential H pylori, Meningococcal, and Leishmaniasis vaccines currently being developed within the scope of the KORTUP (National Platform for Prevention and Treatment), TÜBİTAK 1004 Project in Türkiye. Methods: This study compares findings from three separate economic evaluation models. A Markov modeling approach was employed in all analyses. The primary outcome measures included costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Results were interpreted using willingness-to-pay (WTP) thresholds based on Türkiye’s gross domestic product (GDP) per capita. The base-case threshold was set at USD 15,395, and an alternative scenario threshold of USD 30,790 (twice the base value) was also considered. Results: The comparative analysis indicates that all three vaccine candidates may be cost-effective in Türkiye under specific model assumptions. In the base-case analysis, the ICER was estimated at USD 1,583 per QALY gained for the H pylori vaccine, USD 11,652/QALY for the Meningococcal vaccine, and USD 20,444/QALY for the Leishmaniasis vaccine. Accordingly, the H pylori and Meningococcal vaccines appear to be cost-effective under the GDP per capita threshold of USD 15,395, whereas the Leishmaniasis vaccine may be considered cost-effective only under the higher threshold of USD 30,790. Conclusions: Comparative economic evaluation of vaccine candidates targeting different diseases can support more efficient allocation of limited healthcare resources by prioritizing interventions that generate the greatest societal benefit. Key messages: • The Helicobacter pylori vaccine appears to be the most cost-effective option among the three candidates, followed by the meningococcal and leishmaniasis vaccines. • Assessing the economic value of domestically developed vaccine candidates is strategic for informing national immunization policies and health technology assessment in Türkiye.
SN - 1101-1262
SN - 1464-360X
ER -